Analysts expect Sierra Oncology (NASDAQ:SRRA) to post ($0.22) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Sierra Oncology’s earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.21). Sierra Oncology reported earnings of ($0.26) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.4%. The firm is expected to report its next quarterly earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Sierra Oncology will report full-year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($0.88) to ($0.85). For the next financial year, analysts expect that the company will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.05) to ($0.78). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. During the same quarter in the prior year, the firm posted ($0.30) earnings per share.
Several research firms recently weighed in on SRRA. ValuEngine upgraded shares of Sierra Oncology from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Zacks Investment Research cut shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd.
Shares of NASDAQ SRRA traded up $0.16 during mid-day trading on Tuesday, hitting $1.99. The company had a trading volume of 492,971 shares, compared to its average volume of 594,011. Sierra Oncology has a 12 month low of $1.10 and a 12 month high of $4.09. The stock has a market cap of $142.08, a PE ratio of -2.37 and a beta of 2.38.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its stake in Sierra Oncology by 112.3% during the fourth quarter. Acadian Asset Management LLC now owns 32,437 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 17,161 shares during the period. Cambridge Investment Research Advisors Inc. bought a new position in Sierra Oncology during the fourth quarter worth about $144,000. Jefferies Group LLC bought a new position in Sierra Oncology during the fourth quarter worth about $224,000. Bank of New York Mellon Corp bought a new position in Sierra Oncology during the fourth quarter worth about $280,000. Finally, Two Sigma Investments LP bought a new position in Sierra Oncology during the fourth quarter worth about $489,000. Hedge funds and other institutional investors own 43.33% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Sierra Oncology (SRRA) Expected to Post Earnings of -$0.22 Per Share” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/04/17/sierra-oncology-srra-expected-to-post-earnings-of-0-22-per-share.html.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.